Virax Biolabs enrolls first patients in T-cell dysfunction study

Virax Biolabs (VRAX) has started enrolling patients into its United Kingdom based, multi-center clinical study. Conducted in collaboration with the United Kingdom’s National Health Service, investigators aim to assess the ViraxImmune FluoroSpot T cell assay performance in detecting T cell dysfunction in post-acute infection syndrome patients, including those with long COVID, post-treatment Lyme disease and myalgic encephalomyelitis/chronic fatigue syndrome. As part of the regulatory approval pathway, up to 200 participants will be enrolled into the study, with initial data from this longitudinal assessment expected in Q2 2026.